Randomized Study of Obicetrapib in Combination With Ezetimibe

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-23

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT06005597

Dyslipidemias Hypercholesterolemia Familial Hypercholesterolemia +2 more

COMPLETED PHASE3

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

NCT04753606

Dyslipidemias High Cholesterol Hypercholesterolemia

COMPLETED PHASE2

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

NCT05266586

Dyslipidemias High Cholesterol Hypercholesterolemia

COMPLETED PHASE2

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722

Dyslipidemias High Cholesterol Hypercholesterolemia +2 more

COMPLETED PHASE3

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NCT05425745

Dyslipidemias High Cholesterol Hypercholesterolemia +6 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy. The screening period for this study will take up to 2 weeks. Following the screening period, eligible patients will be randomized to placebo, 5 mg obicetrapib + 10 mg ezetimibe; 5 mg obicetrapib + placebo ezetimibe; or placebo obicetrapib + 10 mg ezetimibe for an 8 week treatment period. After the treatment period, patients will continue for a 4 week safety follow-up and a 8 week PK follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias High Cholesterol Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Placebo-Controlled, Double-Blind, Randomized

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

placebo tablet made to resemble active

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

placebo obicetrapib + placebo ezetimibe; once daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

tablet

Combination therapy

5 mg obicetrapib + 10 mg ezetimibe; once daily

Group Type EXPERIMENTAL

Obicetrapib 5mg

Intervention Type DRUG

tablet

Ezetimibe 10mg

Intervention Type DRUG

tablet

Obicetrapib monotherapy

5 mg obicetrapib + placebo ezetimibe; once daily

Group Type EXPERIMENTAL

Obicetrapib 5mg

Intervention Type DRUG

tablet

Ezetimibe monotherapy

placebo obicetrapib + 10 mg ezetimibe; once daily

Group Type EXPERIMENTAL

Ezetimibe 10mg

Intervention Type DRUG

tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obicetrapib 5mg

tablet

Intervention Type DRUG

Ezetimibe 10mg

tablet

Intervention Type DRUG

Placebo

tablet

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CETP inhibitor Antihyperlipidemic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understanding of the study procedures, willingness to adhere to the study schedules and diet, and agreement to participate in the study by giving written informed consent prior to Screening procedures
* Men or women 18 to 70 years of age, inclusive
* Women may be enrolled if all 3 of the following criteria are met:
* They are not pregnant;
* They are not breastfeeding; and
* They do not plan on becoming pregnant during the study
* Women of childbearing potential must have a negative urine pregnancy test at the Screening Visit.
* Women of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit. Men whose partners are of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit.
* Fasting LDL-C levels \>2.5 mmol/L (\>100 mg/dL) and \<4.5 mmol/L (\<175 mg/dL) and TG levels \<4.5 mmol/L (\<400 mg/dL) (Visit 1) and
* Willingness to maintain a stable diet and physical activity level throughout the study

Exclusion Criteria

* Body mass index \>= 40 kg/m2
* Participation in another clinical study involving an investigational or marketed drug within 30 days prior to the Screening Visit
* Currently taking any lipid-altering therapy
* Any clinical manifestation of atherosclerotic CVD or any evidence of ischemic coronary disease present on the 12-lead ECG at the Screening Visit
* Diagnosis of type 1 or type 2 diabetes mellitus; or HbA1c \>= 6.5% at the Screening visit if no prior diagnosis of diabetes mellitus
* Uncontrolled hypertension ie, sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>90 mmHg taken as the average of triplicate measurements.

One retest will be allowed, at which point if the retest result is no longer exclusionary, the participant may be randomized

* Active muscle disease or persistent creatine kinase concentration \>3 x the upper limit of normal (ULN). One retest will be allowed after 1 week to verify the result, at which point if the retest result is no longer exclusionary, the participant may be randomized
* History of torsades de pointes
* Estimated glomerular filtration rate \<60 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
* Hepatic dysfunction as evidenced by any laboratory abnormality as follows: gamma- glutamyl transferase, alanine aminotransferase, or aspartate aminotransferase \>2 x ULN, or total bilirubin \>1.5 x ULN
* Anemia, defined as hemoglobin concentration \<11 g/dL for males and hemoglobin concentration \<9 g/dL for females
* History of malignancy within the past 5 years, with the exception of non-melanoma skin cancers
* Evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study
* Known ezetimibe or CETP inhibitor allergy or intolerance

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No